<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02638324</url>
  </required_header>
  <id_info>
    <org_study_id>Juhani02</org_study_id>
    <nct_id>NCT02638324</nct_id>
  </id_info>
  <brief_title>Supportive Treatment of Severe Heart Failure by Renal Denervation</brief_title>
  <acronym>Heart-RND</acronym>
  <official_title>Supportive Treatment of Severe Heart Failure by Renal Denervation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Satakunta Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overactivity of sympathetic nervous system is worsening the hemodynamic state of heart&#xD;
      failure patients. The present study is planned to reduce the sympathetic tone in patients&#xD;
      with severe heart failure by renal nervous denervation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patient population consists of heart failure patients who are not responding properly to&#xD;
      medication and biventricular pacing therapy. The inappropriate response to these therapies is&#xD;
      evaluated by patient history (NYHA III-IV), echocardiography (EF &lt; 45%), 6-minute walking&#xD;
      test (&lt;440m) and measurements of P-ProBNP. The patients who fulfill the inclusion criteria&#xD;
      will undergo renal nervous denervation. The patients will be followed up with the same&#xD;
      methods as they were recruited to the study (by patient history (NYHA III-IV),&#xD;
      echocardiography (EF &lt; 45%), 6-minute walking test (&lt;440m) and measurements of P-ProBNP). The&#xD;
      overall time of follow-up will be 24 months. The patients are randomised according to the&#xD;
      waiting list principle in a manner to 1:1. The waiting time will be 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Because of the lack of the candidates and because of restrictions of denervation at the&#xD;
    completion date.&#xD;
  </why_stopped>
  <start_date type="Actual">December 1, 2014</start_date>
  <completion_date type="Actual">January 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6-minute walking test</measure>
    <time_frame>24 months</time_frame>
    <description>Composite outcome measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient history</measure>
    <time_frame>24 months</time_frame>
    <description>Composite outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac echocardiography</measure>
    <time_frame>24 months</time_frame>
    <description>Composite outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P-proBNP</measure>
    <time_frame>24 months</time_frame>
    <description>Composite outcome measure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Renal nervous denervation.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Renal nervous denervation is performed to the patients who do not response properly to conventional therapy. The patients are randomised according to the waiting list principle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal nervous denervation (delayed)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Renal nervous denervation is performed after six months on the waiting list</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Renal nervous denervation</intervention_name>
    <description>The heart failure patients will undergo renal nervous denervation if they have not properly responded to medication and biventricular pacing therapy.</description>
    <arm_group_label>Renal nervous denervation (delayed)</arm_group_label>
    <arm_group_label>Renal nervous denervation.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  NYHA III-IV&#xD;
&#xD;
          -  ejection fraction &lt;45 %&#xD;
&#xD;
          -  6-minute walking test under 440m&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable hemodynamic state&#xD;
&#xD;
          -  uncooperation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mari-Anne Vaittinen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vaasa Central Hospitla</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mari-Anne Vaittinen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vaasa Central Hospital, Vaasa, Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vaasa Central Hospital</name>
      <address>
        <city>Vaasa</city>
        <zip>65130</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 20, 2015</study_first_submitted>
  <study_first_submitted_qc>December 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2015</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal nervous denervation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

